Allspring Global Investments Holdings LLC Sells 596,004 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Allspring Global Investments Holdings LLC trimmed its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 99.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,112 shares of the company’s stock after selling 596,004 shares during the period. Allspring Global Investments Holdings LLC’s holdings in TransMedics Group were worth $207,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Quarry LP lifted its position in shares of TransMedics Group by 557.1% in the third quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after buying an additional 312 shares during the last quarter. National Bank of Canada FI lifted its stake in TransMedics Group by 174.7% during the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after purchasing an additional 262 shares during the last quarter. Farther Finance Advisors LLC grew its position in TransMedics Group by 187.0% in the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after acquiring an additional 316 shares during the last quarter. Hager Investment Management Services LLC bought a new position in TransMedics Group in the 4th quarter valued at approximately $33,000. Finally, Sachetta LLC bought a new stake in TransMedics Group during the 4th quarter worth $40,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Down 5.3 %

Shares of NASDAQ TMDX opened at $73.00 on Wednesday. The business has a 50-day simple moving average of $66.89 and a two-hundred day simple moving average of $103.27. The company has a market cap of $2.45 billion, a P/E ratio of 77.66 and a beta of 2.12. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $177.37. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on TMDX. Piper Sandler reduced their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. Robert W. Baird dropped their price target on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Canaccord Genuity Group dropped their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. Finally, TD Cowen lowered their target price on TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, TransMedics Group presently has an average rating of “Moderate Buy” and an average target price of $122.70.

Insider Buying and Selling at TransMedics Group

In related news, insider Tamer I. Khayal sold 1,084 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total value of $93,657.60. Following the transaction, the insider now directly owns 20,843 shares in the company, valued at approximately $1,800,835.20. This represents a 4.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.00% of the company’s stock.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.